IQVIA BIOTECH

Accelerate early-stage interventions

DOWNLOAD: Advancing Alzheimer’s Disease Therapies

As the global elderly population grows, the urgency to address unmet Alzheimer’s disease (AD) treatment needs intensifies. Biotech and emerging biopharma companies are at the forefront of developing novel therapies aimed at disrupting AD pathology before extensive irreversible damage occurs.

Biotech sponsors can optimize trials by leveraging diagnostic advances — particularly newly characterized blood plasma biomarkers — and novel protocol designs.

In this white paper, we discuss how collaboration with a clinical research organization with deep expertise in neurology and AD can bring transformative therapies to patients faster.

Meet the Authors

Optimize, execute and analyze trials that accelerate clinical development and pathways to approval for AD therapies with a trusted CRO. From innovation to patient impact, we’ve got you.

Complete the form to download the white paper.

First Name *

Last Name *

Business Email *

Job Title *

Company *

Country *

Opt In

By selecting this box, I consent to receiving marketing communications and information about IQVIA's offering by email.

We listen, you succeed, lives improve. Let us know how we can support your clinical development program, bring your innovation to market and maximize patient impact.

address1

Marek Bieniek, M.D.

Senior Director, Medical Strategy,

CNS Center of Excellence, IQVIA

Gijsbert Veerman

Chief Operating Officer,

IQVIA Biotech

DO NOT SELL MY PERSONAL INFORMATION